TSLA -15.475IBM -3.68ARM -12.9CM.TO -0.56V -1.52NRIM 0CSU.TO 149.91NA.TO -1.66
Daily Stock Opinions and Ratings
Stockchase Opinions

Jeff Parent B. Eng. FCSI CIMOncolytics BiotechONC.TODON'T BUYAug 08, 2018

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Jeff Parent B. Eng. FCSI CIMJeff Parent B. Eng. FCSI CIM
No
Unlock Rating
$5.49

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

COMMENT

Oncolytics Biotech(ONC.TO)

Feb 19, 2007
Phase 2 cancer company with some pretty decent results. They are a long way away from where they want to be. Product has huge potential.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$2.41

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
WEAK BUY

Oncolytics Biotech(ONC.TO)

Sep 24, 2004
Not aware of any upcoming short term catalysts. Continuing with their trials. Never had bad results. Very volatile and still early stage.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$7.25

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
WAIT

Oncolytics Biotech(ONC.TO)

Jul 08, 2004
Has a pretty high beta, so the stock goes up and down like a yo-yo. Likes with the company is doing. At some point, a major pharmaceutical company will get interested in their technology. Would like to see more trials and results.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$7.15

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
DON'T BUY

Oncolytics Biotech(ONC.TO)

Sep 09, 2003
If they can find the right deals and get through the clinical trials, the upside would be phenomenal. Very volatile right now.
Photo of Peter HodsonPeter HodsonUnlock Rating
$3.49

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
WEAK BUY

Oncolytics Biotech(ONC.TO)

Jul 10, 2003
A wild stock. Created a virus that could reduce cancer dramatically. Long term potential could be good. Trials have only been small ones. Risky.
Photo of Peter HodsonPeter HodsonUnlock Rating
$3.25

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
WEAK BUY

Oncolytics Biotech(ONC.TO)

Jun 02, 2003
Biotechs have had good moves. Has a ways to go before their drug is on the market. Speculative in the short term.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$4.00

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical
WEAK BUY

Oncolytics Biotech(ONC.TO)

May 06, 2003
Interesting technology. Trials are turning out well, but too small a sampling at this time. Speculative.
Photo of Peter HodsonPeter HodsonUnlock Rating
$2.55

Stock price when the opinion was issued

$1.42

As of Aug 22, 2025. Market Open.

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

SHOP.TO -2.71$151.42
ANET -1.055$151.105
VRT -11.03$278.49
ADBE -3.71$234.17
RBLX -1.22$41.78
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TSLA -15.475$381.205
IBM -3.68$273.81
ARM -12.9$311.96
CM.TO -0.56$153.97
V -1.52$323.53

Popular Articles

Latest Sell Signals

SNOW 1.94$241.6
FLEX -8.73$138.48
MDA.TO 0.27$52.84
CPRT 0.115$31.425
TEVA -0.575$33.875

Most Recent Experts

Kim Bolton

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video